Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerome Moreaux

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Blood|April 17, 2025
Dual targeting of EZH2 and DOT1L in DLBCLJerome Moreaux
Blood|October 3, 2024
KDM6A controls immunogenicity in MMJerome Moreaux
Ebiomedicine|July 3, 2015
SNaPshot as a Valuable Option for the Identification of Mutations in MyelomaJerome Moreaux
Blood|March 4, 2021
The origin of preplasmablastic cellsJerome Moreaux
Methods in Molecular Biology (Clifton, N.J.)|May 26, 2018
Analysis of Global Gene Expression ProfilesAlboukadel Kassambara, Jerome Moreaux
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
Multi-omics tumor profiling technologies to develop precision medicine in multiple myelomaSara Ovejero, Jerome Moreaux
Frontiers in Immunology|April 13, 2023
Editorial: Transcriptional control in normal and malignant B-lymphocytesJerome Moreaux, Alexander A Shtil
Bulletin Du Cancer|July 26, 2018
[EZH2 is therapeutic target for personalized treatment in multiple myeloma]Laurie Herviou, Giacomo Cavalli, Jerome Moreaux
Frontiers in Genetics|October 18, 2019
Treatment May Be Harmful: Mechanisms/Prediction/Prevention of Drug-Induced DNA Damage and Repair in Multiple MyelomaClaire Gourzones, Caroline Bret, Jerome Moreaux
Biochemical and Biophysical Research Communications|November 13, 2012
STEAP1 is overexpressed in cancers: a promising therapeutic targetJerome Moreaux, Alboukadel Kassambara, Dirk Hose, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Blood|April 17, 2025
Dual targeting of EZH2 and DOT1L in DLBCLJerome Moreaux
Blood|October 3, 2024
KDM6A controls immunogenicity in MMJerome Moreaux
Ebiomedicine|July 3, 2015
SNaPshot as a Valuable Option for the Identification of Mutations in MyelomaJerome Moreaux
Blood|March 4, 2021
The origin of preplasmablastic cellsJerome Moreaux
Methods in Molecular Biology (Clifton, N.J.)|May 26, 2018
Analysis of Global Gene Expression ProfilesAlboukadel Kassambara, Jerome Moreaux
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
Multi-omics tumor profiling technologies to develop precision medicine in multiple myelomaSara Ovejero, Jerome Moreaux
Frontiers in Immunology|April 13, 2023
Editorial: Transcriptional control in normal and malignant B-lymphocytesJerome Moreaux, Alexander A Shtil
Bulletin Du Cancer|July 26, 2018
[EZH2 is therapeutic target for personalized treatment in multiple myeloma]Laurie Herviou, Giacomo Cavalli, Jerome Moreaux
Frontiers in Genetics|October 18, 2019
Treatment May Be Harmful: Mechanisms/Prediction/Prevention of Drug-Induced DNA Damage and Repair in Multiple MyelomaClaire Gourzones, Caroline Bret, Jerome Moreaux
Biochemical and Biophysical Research Communications|November 13, 2012
STEAP1 is overexpressed in cancers: a promising therapeutic targetJerome Moreaux, Alboukadel Kassambara, Dirk Hose, et al.
Pageof 4